Mon, October 17, 2022
Sat, October 15, 2022
Fri, October 14, 2022
Thu, October 13, 2022
Wed, October 12, 2022
Tue, October 11, 2022

Matthew Harrison Maintained (ALNY) at Hold with Decreased Target to $220 on, Oct 13th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-220-on-oct-13th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $222 to $220 on, Oct 13th, 2022.

Matthew has made no other calls on ALNY in the last 4 months.



There are 10 other peers that have a rating on ALNY. Out of the 10 peers that are also analyzing ALNY, 5 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gary Nachman of "BMO Capital" Maintained at Hold with Increased Target to $200 on, Friday, September 9th, 2022
  • David Lebowitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $164 on, Friday, July 15th, 2022
  • Olivia Brayer of "Cantor Fitzgerald" Initiated at Hold and Held Target at $175 on, Wednesday, July 13th, 2022
  • Debjit Chattopadhyay of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, June 27th, 2022
  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $98 on, Wednesday, June 15th, 2022


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Maury Raycroft of "Jefferies" Maintained at Strong Buy with Increased Target to $232 on, Monday, October 3rd, 2022
  • Luca Issi of "RBC Capital" Maintained at Buy with Increased Target to $250 on, Tuesday, September 20th, 2022
  • Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $256 on, Friday, September 9th, 2022
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $240 on, Thursday, August 4th, 2022
  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $250 on, Thursday, August 4th, 2022

Publication Contributing Sources